The relationship between serum levels of miR⁃200a and miR⁃152 and the prognosis of patients with gestational trophoblastic neoplasia undergoing chemotherapy
Received date: 2023-06-26
Online published: 2023-11-15
目的 探讨血清微小RNA-200a（miR-200a）、微小RNA-152（miR-152）在妊娠滋养细胞肿瘤（GTN）预后中的作用。 方法 选取100例GTN化疗患者为观察组，根据化疗疗效将患者分为预后良好组80例和预后不良组20例；选取同期体检健康女性103例为对照组。采用实时荧光定量PCR法检测血清miR-200a、miR-152表达水平。 结果 观察组血清miR-200a表达水平高于对照组，miR-152表达水平低于对照组（P < 0.05）。随化疗时间延长，预后良好组与预后不良组血清miR-200a表达水平依次降低，miR-152表达水平依次升高（P < 0.05）。预后不良组化疗前后血清miR-200a表达水平高于预后良好组，miR-152表达水平低于预后良好组（P < 0.05）。预后良好组与预后不良组国际妇产科联盟（FIGO）预后评分、化疗前血HCG水平比较，差异有统计学意义（P < 0.05）。化疗前血清miR-200a、miR-152表达水平单独及联合预测GTN化疗患者预后不良的AUC分别为0.793、0.844、0.887。miR-200a、miR-152、FIGO预后评分≥ 7分与GTN化疗患者预后不良有关（P < 0.05）。 结论 化疗前高表达miR-200a，低表达miR-152可能与GTN化疗患者预后不良有关，可为化疗预后评估提供参考。
关键词： 妊娠滋养细胞肿瘤; 化疗; 微小RNA-200a; 微小RNA-152; 预后
吴静 , 赵妍 , 张珂 , 杨景 , 孟胜君 . 血清miR-200a、miR-152水平与妊娠滋养细胞肿瘤化疗患者预后的关系[J]. 实用医学杂志, 2023 , 39(20) : 2623 -2628 . DOI: 10.3969/j.issn.1006-5725.2023.20.012
Objective This study mainly explores the role of serum microRNA-200a （miR-200a） and microRNA-152 （miR-152） in gestational trophoblastic tumors （GTN） prognosis. Methods One-hundred GTN chemotherapy patients who treated in our hospital were collected as the observation group， according to the efficacy of chemotherapy， patients were divided into the good prognosis group （80 cases） and the poor prognosis group （20 cases）； 103 healthy women who underwent physical examination were collected as the control group. Real-time fluorescence quantitative PCR method was applied to detect the expression levels of miR-200a and miR-152 in serum. Results The serum miR-200a expression level in the observation group was higher than that in the control group， while the miR-152 expression level was lower than that in the control group （P < 0.05）. With the prolongation of chemotherapy time， the expression level of miR-200a in the serum of the good prognosis group and the poor prognosis group decreased sequentially， while the expression level of miR-152 increased sequentially （P < 0.05）. The expression level of miR-200a in the serum of the poor prognosis group before and after chemotherapy were higher than that of the good prognosis group， while the expression level of miR-152 was lower than that of the good prognosis group （P < 0.05）. There was a statistically significant difference in the International Federation of Obstetrics and Gynecology （FIGO） prognosis score and pre chemotherapy blood HCG levels between the group with good prognosis and the group with poor prognosis （P < 0.05）. The AUC of predicting poor prognosis in GTN chemotherapy patients with serum miR-200a and miR-152 expression levels before chemotherapy alone and in combination were 0.793， 0.844， and 0.887， respectively. MiR-200a， miR-152， and FIGO prognosis scores≥7 are associated with poor prognosis in GTN chemotherapy patients （P < 0.05）. Conclusion High expression of miR-200a and low expression of miR-152 before chemotherapy may be associated with poor prognosis in GTN chemotherapy patients， which can provide reference for the evaluation of chemotherapy prognosis.
| 1 | LUKINOVIC N， MALOVRH E P， TAKAC I， et al. Advances in diagnostics and management of gestational trophoblastic disease［J］. Radiol Oncol， 2022， 56（4）：430-439. |
| 2 | WANG Y X， CUI L， WU W B， et al. Downregulation of PDCD4 by deSUMOylation associates with the progression of gestational trophoblastic disease［J］. Placenta， 2022， 130（1）：17-24. |
| 3 | SILVA A L M D， MONTEIRO K D N， SUN S Y， et al. Gestational trophoblastic neoplasia： Novelties and challenges［J］. Placenta， 2021， 116（1）：38-42. |
| 4 | 吴齐斌， 宋一一， 祝建芳， 等. Nanog和p53蛋白在妊娠滋养细胞疾病中的表达及临床意义［J］. 中国妇产科临床杂志， 2020， 21（2）：179-183. |
| 5 | WU G M， JIN Y， CAO Y M， et al. The diagnostic value and regulatory mechanism of miR-200a targeting ZEB1 in pregnancy-induced hypertension［J］. Hypertens Pregnancy， 2020， 39（3）：243-251. |
| 6 | ZHANG L， YUAN J M， ZHAO R H， et al. Correlation of MiR-152 expression with VEGF expression in placental tissue of preeclampsia rat and its influence on apoptosis of trophoblast cells［J］. Eur Rev Med Pharmacol， 2019， 23（9）：3553-3560. |
| 7 | NGAN H Y S， SECKL M J， BERKOWITZ R S， et al. Diagnosis and management of gestational trophoblastic disease： 2021 update［J］. Int J Gynaecol Obstet， 2021， 155（1）：86-93. |
| 8 | BUZA N. Gestational trophoblastic disease： contemporary diagnostic approach［J］. Surg Pathol Clin， 2022， 15（2）：197-218. |
| 9 | HOEIJMAKERS Y M， SIMONS M， BULTEN J， et al. PD-L1 in gestational trophoblastic disease： an antibody evaluation［J］. Acta Obstet Gynecol Scand， 2022， 101（9）：1007-1016. |
| 10 | 陈梦捷， 梁月娟， 万兵， 等. 高预后评分妊娠滋养细胞肿瘤患者化疗疗效及耐药因素分析［J］. 中华肿瘤防治杂志， 2020， 27（4）：310-315. |
| 11 | JIN M， XU Q， LI J， et al. Micro-RNAs in human placenta： tiny molecules， immense power［J］. Molecules， 2022， 27（18）：5943-5961. |
| 12 | 陈希妍， 马彦娟， 牛丽丹， 等. 缺糖缺氧心肌细胞中miRNA-155对Notch信号通路及自噬和凋亡的影响［J］. 实用医学杂志， 2021， 37（3）：304-307. |
| 13 | NING W， WU B， CHEN Y， et al. Role of microRNAs regulating trophoblast cell function in the pathogenesis of pre?eclampsia （Review）［J］. Exp Ther Med， 2022， 25（1）：50-58. |
| 14 | YE Z， WANG S， HUANG X， et al. Plasma exosomal miRNAs associated with metabolism as early predictor of gestational diabetes mellitus［J］. Diabetes， 2022， 71（11）：2272-2283. |
| 15 | HAYDER H， SHAN Y， CHEN Y， et al. Role of microRNAs in trophoblast invasion and spiral artery remodeling： Implications for preeclampsia［J］. Front Cell Dev Biol， 2022， 10（1）：1-24. |
| 16 | LIANG L， CHEN Y， WU C， et al. MicroRNAs： key regulators of the trophoblast function in pregnancy disorders［J］. J Assist Reprod Genet， 2023， 40（1）：3-17. |
| 17 | LI P， LIU X， XING W， et al. Exosome-derived miR-200a promotes esophageal cancer cell proliferation and migration via the mediating Keap1 expression［J］. Mol Cell Biochem， 2022， 477（4）：1295-1308. |
| 18 | KLICKA K， GRZYWA T M， MIELNICZUK A， et al. The role of miR-200 family in the regulation of hallmarks of cancer［J］. Front Oncol， 2022， 12（1）：1-37. |
| 19 | KHALIL E H， SHAKER O G， HASONA N A. Impact of rs2107425 polymorphism and expression of lncH19 and miR-200a on the susceptibility of colorectal cancer［J］. Indian J Clin Biochem， 2023， 38（3）：331-337. |
| 20 | 刘莹， 刘海娟， 黄志娟. miR-200a-3p靶向转甲状腺素蛋白对妊娠期高血压疾病滋养细胞生物学行为的影响［J］. 广西医科大学学报， 2021， 38（1）：1-8. |
| 21 | LIN T， YU C C， LIAO Y W， et al. miR-200a inhibits proliferation rate in drug-induced gingival overgrowth through targeting ZEB2［J］. J Formos Med Assoc， 2020， 119（8）：1299-1305. |
| 22 | HUANG Y， BAO T， LI Z， et al. Function of miR-200a in proliferation and apoptosis of non-small cell lung cancer cells［J］. Oncol Lett， 2020， 20（2）：1256-1262. |
| 23 | TIAN Y， LI L， LIN G， et al. lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p［J］. Leuk Lymphoma， 2021， 62（7）：1574-1584. |
| 24 | WANG Y， WU X Q， CAI J R， et al. SIRT7 silencing by miR-152-3p confers cell apoptosis and renal functional impairment induced by renal ischaemia/reperfusion injury［J］. Int Urol Nephrol， 2023， 55（2）：367-376. |
| 25 | FABOVá Z， KISLíKOVá Z， LONCOVá B， et al. MicroRNA miR-152 can support ovarian granulosa cell functions and modify apigenin actions［J］. Domest Anim Endocrinol， 2023， 3（1）：84-85. |
/
| 〈 |
|
〉 |